Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
Status:
Not yet recruiting
Trial end date:
2022-08-04
Target enrollment:
Participant gender:
Summary
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks
prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone
or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed
at 3 weeks. Following surgery, patients will receive standard of care HER2-directed and
endocrine therapy at the treating physician's discretion.